Lantern Pharma (LTRN) Accumulated Expenses (2020 - 2021)

Lantern Pharma's (LTRN) quarterly Accumulated Expenses came in at $914000.0 in Q3 2021, up 78.52% on a QoQ basis from $512000.0 in Q2 2021.

Lantern Pharma (LTRN) Accumulated Expenses (2020 - 2021) Analysis & Trends

Lantern Pharma (LTRN) has 2 years of Accumulated Expenses data on file, last reported at $914000.0 in Q3 2021.

Quarterly Accumulated Expenses changed N/A year-over-year to $914000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $914000.0 (changed N/A YoY) and the FY2020 annual result came in at $120000.0, changed N/A from the prior year.
Accumulated Expenses improved to $914000.0 in Q3 2021, from $512000.0 in the prior quarter.
In the past five years, Accumulated Expenses ranged from a high of $914000.0 in Q3 2021 to a low of $23000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lantern Pharma	26.05 Mn	26.05 Mn	-

Download Data